IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
337Homocystinuria4

337. Homocystinuria


Clinical trials : 13 Drugs : 13 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 23
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-000614-21-AT
(EUCTR)
09/08/200716/06/2006A multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuriaA multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuria homocystinuria
MedDRA version: 8.1;Level: pref;Classification code 10020365
Product Name: Prefolic
INN or Proposed INN: 5-MTHF
Other descriptive name: IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino
Zambon Group S.p.ANULLNot RecruitingFemale: yes
Male: yes
22Hungary;United Kingdom;Italy;Austria
2EUCTR2006-000614-21-HU
(EUCTR)
13/11/200615/08/2006A multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuriaA multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuria homocystinuria
MedDRA version: 8.1;Level: pref;Classification code 10020365
Product Name: Prefolic
INN or Proposed INN: 5-MTHF
Other descriptive name: IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino
Zambon Group S.p.ANULLNot RecruitingFemale: yes
Male: yes
22Phase 2Hungary;Slovakia;Austria;United Kingdom
3EUCTR2006-000614-21-GB
(EUCTR)
13/10/200620/09/2006A multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuriaA multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuria homocystinuria
MedDRA version: 8.1;Level: pref;Classification code 10020365
Trade Name: Prefolic
INN or Proposed INN: 5-MTHF
Other descriptive name: IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino
Zambon Group S.p.ANULLNot RecruitingFemale: yes
Male: yes
22Hungary;United Kingdom;Italy;Austria
4EUCTR2006-000614-21-SK
(EUCTR)
20/09/200612/07/2006A multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuriaA multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital homocystinuria homocystinuria
MedDRA version: 8.1;Level: pref;Classification code 10020365
Product Name: Prefolic
INN or Proposed INN: 5-MTHF
Other descriptive name: IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino
Zambon Group S.p.ANULLNot RecruitingFemale: yes
Male: yes
22Phase 2Hungary;Slovakia;Austria;United Kingdom